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Abstract
Background: HIV-infected drug users are at higher risk of non-adherence and poor treatment outcomes than HIV-
infected non-drug users. Prior work from our group and others suggests that directly administered antiretroviral
therapy (DAART) delivered in opioid treatment programs (OTPs) may increase rates of viral suppression.
Methods/Design: We are conducting a randomized trial comparing DAART to self-administered therapy (SAT) in 5
OTPs in Baltimore, Maryland. Participants and investigators are aware of treatment assignments. The DAART
intervention is 12 months. The primary outcome is HIV RNA < 50 copies/mL at 3, 6, and 12 months. To assess
persistence of any study arm differences that emerge during the active intervention, we are conducting an 18-month
visit (6 months after the intervention concludes). We are collecting electronic adherence data for 2 months in both
study arms. Of 457 individuals screened, a total of 107 participants were enrolled, with 56 and 51 randomly assigned
to DAART and SAT, respectively. Participants were predominantly African American, approximately half were women,
and the median age was 47 years. Active use of cocaine and other drugs was common at baseline. HIV disease stage
was advanced in most participants. The median CD4 count at enrollment was 207 cells/mm
3, 66 (62%) had a history
of an AIDS-defining opportunistic condition, and 21 (20%) were antiretroviral naïve.
Conclusions: This paper describes the rationale, methods, and baseline characteristics of subjects enrolled in a
randomized clinical trial comparing DAART to SAT in opioid treatment programs.
Trial Registration: ClinicalTrials.gov: NCT00279110
Background
Founded on the successful model of directly observed
therapy for tuberculosis [1], directly administered antire-
troviral therapy (DAART) for HIV-infected individuals
has been evaluated in several contexts [2-4]. To date,
trials have yielded mixed results regarding the efficacy
of DAART for increasing adherence and viral suppres-
sion rates compared to self-administered therapy (SAT).
A meta-analysis of randomized trials found no benefit
for DAART relative to SAT for viral load suppression
[2]. In contrast, a second meta-analysis, which included
both randomized and non-randomized comparative stu-
dies, found DAART to be statistically significantly asso-
ciated with a higher likelihood of viral suppression and
larger CD4 cell increases compared to SAT [3]. Both
meta-analyses reported trends for greater DAART bene-
fit in studies conducted in drug-using compared to non-
drug-using populations.
Medication assisted therapy with methadone or bupre-
norphine in opioid treatment programs (OTPs) is effec-
tive treatment for opioid addiction, and entails frequent
contact with patients that may facilitate DAART [5,6].
Based on developmental work at our center [7], we
hypothesized that providing DAART to HIV-infected
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To address this question we designed a randomized
controlled trial of DAART compared with SAT. In this
paper we describe the rationale, methods, and baseline
characteristics of subjects enrolled in our study.
Methods
Design
The study is a randomized, non-blinded trial comparing
DAART and SAT in HIV-infected participants who are
receiving medication assisted treatment at 1 of 5 OTPs
in Baltimore, Maryland. In the DAART intervention,
study assistants observe morning doses of antiretroviral
therapy (ART) on weekdays when participants attend
the OTP; other doses are self-administered. Participants
in the control arm self-administer all doses. The primary
outcome is viral load suppression, measured at 3, 6, and
12 months. We provide DAART for up to 12 months,
after which participants assigned to this arm convert to
self-administration. We follow participants to 18 months
to assess the potential persistence of any benefits rea-
lized during the intervention period.
Setting
We enrolled participants from 5 OTPs in Baltimore
between May 2006 and May 2010. Initially, the study
began with three sites (1, 2, and 3). However, we discon-
tinued recruitment at site 3 due to slow enrollment and
replaced it with sites 4 and 5 in August 2007 and
August 2008, respectively. Three programs were hospi-
tal-affiliated OTPs (sites 1, 3, and 5), and two were inde-
pendent programs (sites 2 and 4). The OTP censuses
ranged from 153 to 1007. All sites provided methadone
maintenance therapy, and site 1 also provided buprenor-
phine maintenance therapy. Sites 1 and 5 had on-site
HIV care available throughout the study, sites 2 and 3
had on-site HIV care available for part of the study per-
iod, and site 4 did not have on-site HIV-care services.
Eligibility
Individuals were eligible for the study if they were 18
years of age or older, HIV seropositive, had received
maintenance therapy with methadone or buprenorphine
for > 3 weeks with no plans to discontinue, and had an
identified HIV provider and active insurance coverage
for ART. Moreover, to be included in the study, we
required participants to be ART experienced or (if treat-
ment naïve) eligible for ART according to March 23,
2004 Department of Health and Human Services guide-
lines for treatment [8], which included history of oppor-
tunistic condition, HIV-related symptoms, CD4 count <
350 cells/mm
3, or HIV RNA > 55,000 copies/mL. ART
regimens were prescribed by HIV providers prior to ran-
domization and had to include ≥ 3d r u g s ,i n c l u d i n ga
protease inhibitor, non-nucleoside reverse transcriptase
inhibitor, abacavir, or integrase inhibitor. Additionally,
we required verbal agreement to participate from parti-
cipants’ HIV medical providers. Exclusion criteria
included stable ART use with HIV RNA < 500 copies/
mL, ART dosed more frequently than twice daily, use of
liquid antiretroviral preparations, participation in
another HIV adherence program in which medication is
directly administered, or fewer than 1.5 ‘active’ drugs in
the specified regimen - as predicted by prior genotypic
resistance tests (if available) and mutation interpretation
guidelines [9].
Participant Recruitment
Research assistants, employed full-time at the sites and
familiar with the OTP clients, were responsible for
recruitment and initial screening of participants. We
posted study flyers at all sites and made regular presen-
tations to counselors, intake specialists, and administra-
tors to describe the purpose of the study and request
referral of HIV-infected clients for screening. Addition-
ally, we facilitated on-site HIV counseling and testing
services at the sites to improve access to testing and to
identify HIV-infected persons who were not aware of
their status. The research assistants and study coordina-
tor obtained and reviewed medical records and con-
tacted HIV care providers to obtain their agreement to
participate.
Human Subjects Protection
The study was approved by the Johns Hopkins Medicine
Institutional Review Board, the University of Maryland
Baltimore Institutional Review Board, and the Veterans
Administration Research and Development Committee.
Participants provided written informed consent, and
were encouraged to take the consent document home to
discuss with family or medical providers prior to joining
the study. We also asked participants to sign releases for
medical and substance abuse treatment records to per-
mit confirmation of study eligibility and to record out-
come data during the trial. To protect confidentiality,
unique study identification numbers were used on all
case report forms and clinical samples. We stored hard
copies of study records in locked filing cabinets inside
locked offices. We store electr o n i cd a t ao nap a s s w o r d -
protected laptop computer that was backed-up each
night to a secure server. We obtained a Certificate of
Confidentiality from the National Institute on Drug
Abuse to further protect sensitive participant data.
Randomization
To prevent knowledge of treatment assignment from
influencing the selection of antiretroviral drugs, we
required HIV providers to prescribe ART regimens
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investigators (GML) generated random treatment
assignments to DAART and SAT in a 1:1 ratio, stratified
by study site and ART exposure at baseline (naïve or
experienced), using a commercial statistical software
package. Assignments were generated in blocks that ran-
d o m l yv a r i e di ns i z eb e t w e e n2a n d8 .T h et r e a t m e n t
assignment list was incorporated into a Microsoft
Access-based program that revealed individual assign-
ments sequentially as new participants were enrolled.
When enrollment criteria were fulfilled for a new parti-
cipant, the study coordinator obtained the treatment
assignment by activating the “randomize” function in
the computer program. The assignment list was pass-
word protected and was not accessible to the research
coordinator or research assistants, apart from revealing
sequential treatment assignments at the times of
randomization.
Participant Follow-up
We conducted study visits at baseline, 3, 6, 12, and 18
months. Study visits were conducted at OTPs and
included an update of contact information, a face-to-
face interview, and collection of blood and urine speci-
mens. We measured CD4 cell counts (flow cytometry)
and HIV RNA levels (AMPLICOR HIV-1 Monitor Test,
version 1.5, Roche Diagnostics, Basel, Switzerland) from
blood. We stored plasma samples from baseline and fol-
low-up visits so that acquisition of drug resistance dur-
ing the study period can be assessed. Urine samples
were screened for methadone, opiates, cocaine, oxyco-
done, and benzodiazepines by enzyme immunoassay.
Results of urine drug screens were not released to any-
one outside of the study without written consent from
participants.
The interviews addressed demographic and socioeco-
nomic information, perceived availability of social sup-
port, depressive symptoms (Center for Epidemiologic
Studies Depression Scale [CESD] short form [10]), anxi-
ety symptoms (anxiety subscale of Brief Symptom
Inventory [11]), self-reported ART adherence (3-day and
2-week recall of missed doses [12]), alcohol use (Alcohol
Use Disorders Identification Test [13]), drug use (Johns
Hopkins HIV Clinical Cohort Instrument [12]), health-
related quality of life (visual analogue scale), and emer-
gency department visits and hospitalizations in the prior
3 months.
The study coordinator conducted all study visits. This
was done to both standardize data collection and to fos-
ter candid responses from participants about medication
adherence, substance use, and other sensitive issues.
The study coordinator had no role in participants’ sub-
stance abuse treatment or in delivery of the DAART
intervention, which was managed by research assistants
at the sites. Additionally, study staff abstracted data
from participants’ OTP substance abuse treatment
records and from HIV clinic records every 3 months,
including changes in methadone or buprenorphine dose,
urine drug test results, CD4 cell counts, HIV RNA
levels, opportunistic conditions, and changes to ART.
We made concerted efforts to maintain contact with
participants (particularly if they left the OTP) and made
arrangements for study visits to be completed in another
venue if preferred. We updated telephone and mailing
address contact information at each encounter and also
collected contact information for relatives that would be
likely to know participants’ whereabouts. We reim-
bursed participants for completing study visits.
DAART Arm
Two specialty pharmacies packaged medications for the
DAART arm in single-dose clear plastic bags that were
labeled with medication and dosing information as spe-
cified in Maryland State regulations. When participants
attended the OTP for methadone or buprenorphine they
went to a private office where a research assistant or a
methadone nurse observed them take an ART dose.
While other investigators have administered ART and
methadone simultaneously from OTP dosing windows
[6,14], participants in our pilot project found that this
approach was stressful and jeopardized their confidenti-
ality [7]. We provided participants with take-home ART
doses (packaged identically to observed doses) for eve-
nings (when required by a twice-daily dosing schedule),
weekends, holidays, and weekdays when participants did
not have to attend the OTP (i.e., methadone take-home
days). We maintained close contact with the medical
p r o v i d e r sa n da s k e dt h e mt on o t i f yu sp r o m p t l yo f
changes to the ART regimen and to send new prescrip-
tions to us by facsimile so that medication could be pre-
pared for observed dosing. DAART participants were
also supplied with three days of “emergency doses” to
use if they did not attend the OTP as scheduled. Emer-
gency doses are replenished as needed.
SAT Arm
SAT participants self-administered all ART doses. We
did not provide adherence counseling, coaching, or feed-
back to SAT participants. SAT participants were free to
engage in adherence programs offered by their HIV
clinics.
Safety Monitoring
We alerted patients and HIV medical providers about
potential drug interactions between methadone and
antiretroviral drugs that were prescribed. In particular,
we assured that participants and providers were aware
of the potential for non-nucleoside reverse transcriptase
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which can cause clinically significant opioid withdrawal
symptoms [15,16]. We also notified participants’ counse-
lors and OTP clinicians so that methadone doses could
be adjusted in a timely fashion if needed.
Electronic Adherence Monitoring
We used MEMS VI Track Caps( A a r d e xG r o u p ,Z u g ,
Switzerland) for electronic adherence monitoring (EAM)
for the first 2 months of the study in both arms.
Because these devices are not compatible with pill-
boxes, the EAM substudy was not required if partici-
pants preferred to use pill boxes. We selected one
medication from each participant’sA R Tr e g i m e nf o r
EAM according to the following selection criteria hierar-
chy: 1) medication dosed twice daily, 2) combination
preparation, containing two or three antiretroviral
drugs, 3) protease inhibitor (excluding ritonavir if only
used for pharmacokinetic boosting), or 4) non-nucleo-
side reverse transcriptase inhibitor. Research assistants
met with participants to initiate EAM when the new
regimen was started. Research assistants instructed par-
ticipants on the use of EAM devices (with verbal and
written instructions), activated new EAM caps, com-
pleted quality control protocols, and placed caps on
medication bottles. Participants returned for EAM visits
at approximately 10 days, 4 weeks, and 8 weeks. At the
each of these visits, research assistants downloaded data
from the EAM devices, completed a debriefing form to
identify non-adherence with use of the devices, reviewed
instructions for proper use of EAM devices, performed
quality control checks, counted leftover pills, and refilled
the monitored medication with a new 30-day supply if
needed (i.e., at 4-week visit). Research assistants did not
discuss EAM data or provide feedback to participants.
We reimbursed participants for attending EAM visits
and returning EAM devices.
We modified the procedures described above for par-
ticipants assigned to DAART. As with SAT participants,
DAART participants took home an EAM device for
their monitored medication and they were instructed to
take medication from the EAM device whenever they
took a “home” dose (e.g., evening or weekend doses).
We used a second EAM device to monitor observed
doses delivered at the OTP. For observed doses, the
research assistant removed a dose from the EAM device
and gave it to the participant to take (in addition to
other medications used in the regimen). In subjects
assigned to DAART, data from the “home” and “OTP”
EAM devices will be combined for analyses.
Power and Planned Statistical Analyses
The primary study outcome is suppression of HIV RNA
< 50 copies/mL. We hypothesize that DAART will
increase rates of viral suppression compared to SAT. At
study outset, we planned to enroll 200 participants to
provide 80% power to detect a 20% difference in HIV
RNA suppression between the study arms at 12 months.
However, enrollment was slower than anticipated
because limited numbers subjects met the eligibility cri-
teria. When addition of new study sites failed to fully
rectify slow recruitment, we revised our primary out-
come to viral suppression at three time points during
active intervention (3, 6, and 12 months), rather than at
as i n g l et i m ep o i n t( 1 2m o n t h s ) .U s i n gar e p e a t e dm e a -
sures analytic approach, we calculated that a sample size
of 120, assuming 15% loss to follow-up (i.e. effective
sample size of 50 in each arm) and an intra-subject cor-
relation of 0.2, will provide greater than 84% power to
detect a 20% average difference in viral load suppression
between the arms, given SAT viral suppression rates
between 25% and 40%.
Secondary outcomes include HIV RNA < 400 copies/
mL, change in log10 HIV RNA, change in CD4 cell
count, cumulative use of ART, retention to the OTP,
and acquisition of new antiretroviral resistance muta-
tions. We will also evaluate differences in viral suppres-
sion at 18 months (6 months following the conclusion
of the intervention) to assess for persistence of interven-
tional effects. Finally, we will compare EAM in the
study arms. We will use chi-squared and Wilcoxon rank
sum tests to compare categorical and continuous vari-
ables, respectively. We will use mixed effects logistic
and linear models to assess longitudinal outcomes. The
primary analysis of viral suppression will be intent-to-
treat, with missing values excluded. In sensitivity ana-
lyses, we will consider missing values to be failures and
construct bounds for the potential bias.
Participant Enrollment and Disposition
A total of 457 individuals were screened for the study
(Figure 1). Of these, 338 were ineligible after screening
and record review and 12 declined to participate. The
most common reason for ineligibility was current ART
use with suppressed viral load (n = 237), followed by
disengagement in HIV care, lack of medication insur-
ance, or failure to obtain an ART prescription (n = 59).
A total of 107 participants were enrolled, with 51
assigned to SAT and 56 assigned to DAART. Compared
to participants enrolled to the trial, the 12 individuals
who declined to participate were more likely to be from
site 4 and less likely to be African American (Table).
Joiners and non-joiners were similar with respect to sex
and age.
Study sample characteristics
A median of 14 participants were enrolled at each of the
five participating OTPs (range 8 to 39). Study
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approximately half were women, and the median age
was 47 years (Table 1.). Fifty two percent of subjects
had completed high school or a general equivalency
diploma. Only 15% of participants were employed. Parti-
cipants had received medication-assisted therapy at the
OTP for a median of 11 months prior to enrollment,
with a median methadone dose of 90 mg or a median
buprenorphine dose of 19 mg. Forty percent and 20%
were urine screen positive for cocaine and opiates,
respectively, at study enrollment.
In general, study participants had advanced HIV dis-
ease, 62% had a history of Centers for Disease Control
and Prevention Category C opportunistic conditions
[17], the median nadir CD4 count was 102 cells/mm
3,
the median current CD4 was 207 cells/mm
3,a n dt h e
median HIV RNA levels was 4.7 log10 copies/mL.
Twenty percent of subjects were ART naïve at enroll-
ment, and the prescribed regimen was dosed once daily
in 61% and twice daily in 39%. Nearly 80% of partici-
pants were treated with protease inhibitor-based regi-
mens, the majority of which were ritonavir-boosted.
Discussion
This study is designed to assess the efficacy of DAART
compared to SAT among HIV-infected subjects attend-
ing OTPs for maintenance methadone or buprenorphine
therapy, and builds upon our developmental work with
DAART in this setting [7,18]. Our study is the second
randomized controlled trial of DAART in OTPs.
A recent study from the Bronx, New York, found that
OTP-based DAART was associated with statistically sig-
nificantly higher rates of adherence and viral suppres-
sion than SAT [6]. OTPs are attractive settings to
deliver DAART because HIV-infected drug users are at
higher risk for non-adherence [19] and suboptimal ART
outcomes [20] compared to other HIV risk groups, and
OTP regulations necessitate frequent contact with
patients.
To date, trials of DAART have yielded mixed findings
regarding efficacy [2,3]. However, completed trials have
varied considerably in setting, population studied, and
method of delivering DAART. For example, trials have
been conducted in resource-rich [6,21-24] or resource-
poor settings [25-28], enrolled predominantly ART-
Screened for eligibility
(n = 457)
Total enrolled 
(n = 107)
Ineligible after screening and record review
(n= 338)
HIV-negative (n=1)
Not receiving or discontinuing methadone or 
buprenorphine (n=31)
Not engaged in HIV care, no medication insurance 
coverage, or did not obtain ART prescription (n=59)
Treatment naïve and did not meet DHHS guidelines 
for ART initiation (n=6)
Stable ART use with suppressed viral load (n=237)
Enrolled in another directly administered therapy 
program (n=3)
Documented drug resistance with fewer than 1.5 drugs 
in regimen predicted to be active (n=1)
DAART
(n = 56)
SAT
(n = 51)
Declined to participate
(n=12)
Figure 1 Disposition of individuals screened for a trial comparing directly administered antiretroviral therapy to self-administered
therapy in opioid treatment programs, Baltimore, Maryland. ART, antiretroviral therapy; DHHS, Department of Health and Human Services;
DAART, directly administered antiretroviral therapy; SAT, self-administered therapy.
Mullen et al. BMC Infectious Diseases 2011, 11:45
http://www.biomedcentral.com/1471-2334/11/45
Page 5 of 9Table 1 Baseline characteristics of HIV-infected participants enrolled in a randomized trial comparing directly
administered antiretroviral therapy to self administered therapy in opioid treatment programs, Baltimore, Maryland
Characteristic Enrolled in study
a (n = 107) Declined to participate
a (n = 12)
Opioid treatment program (enrollment site)
1 39 (36) 2 (17)
2 35 (33) 1 (8)
3 8 (8) 0
4 14 (13) 9 (75)
5 11 (10) 0
Female 51 (48) 7 (58)
Race
African American 88 (82) 7 (58)
Caucasian/other 19 (18) 5 (42)
Age, years 47 (41-51) 46 (38-51)
Education
Less than high school graduate 51 (48)
High school graduate or equivalent 36 (34)
Any college, n (%) 20 (19)
Marital status
Married or live with partner 17 (16)
Never married 54 (51)
Widowed 9 (8)
Divorced or separated 27 (25)
Considers himself/herself to be homeless 32 (30)
Housing/living situation
Own a house 3 (3)
Rent an apartment/house 49 (46)
Stay with family or friends 35 (33)
Residential drug treatment 5 (5)
Other residential facility or institution 11 (10)
Live on street or in single room occupancy hotel 4 (4)
Employed 16 (15)
Duration of methadone or buprenorphine treatment, months 11 (2-49)
Receiving methadone 99 (93)
Methadone dose, mg 90 (70-120)
Receiving buprenorphine 8 (7)
Buprenorphine dose, mg 19 (14-27)
Depression score
b 11 (5-15)
Urine drug test, positive results
Cocaine 42 (40)
c
Benzodiazepine 14 (13)
c
Opiate (morphine/codeine) 21 (20)
c
Oxycodone 1 (1)
c
Nadir CD4 count, cells/mm
3 102 (30-218)
Current CD4 count, cells/mm
3 182 (69-309)
HIV RNA log10 copies/mL 4.7 (4.0-5.1)
Hospitalized in prior 3 months 34 (32)
Prior AIDS-defining opportunistic condition 66 (62)
Hepatitis C antibody positive 87 (81)
Antiretroviral naive 21 (20)
Category of prescribed antiretroviral regimen
PI + NRTIs 83 (78)
NNRTI + NRTIs 16 (15)
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enrolled unselected participants [21,24,25,27,28] or par-
ticipants with adherence barriers [6,22,23], and used
healthcare workers [21-23] or unpaid peers (often family
or friends) [6,24-28] to deliver DAART. Additionally,
trials have differed in methodological factors including
sample size, duration of intervention, primary outcome,
method of measuring adherence, and follow-up after
completion of the DAART intervention.
Our study has several strengths. First, our target
population is HIV-infected drug users (most with
demonstrated non-adherence in previous treatment
attempts). Of completed DAART trials, those targeting
individuals with documented non-adherence, active drug
use, or other adherence barriers have been more likely
to show efficacy compared to studies enrolling primarily
unselected and ART-naïve participants [2,3,29,30].
Moreover, labor intensive adherence interventions are
m o s tl i k e l yt ob ec o s t - e f f e c t ive when delivered to those
at highest risk of poor outcomes [31]. Second, ours is
one of the only trials to assess the efficacy of DAART
over 12 months. Two other studies that assessed
DAART interventions for 12 months were conducted in
sub-Saharan Africa and used peers to observe dosing
[25,28]. Third, similar to other studies [24-27,32], our
study will assess the persistence of any treatment arm
differences that emerge during the intervention period
at a post-intervention follow-up visit. Fourth, as has
been done in other studies [33-35], we will assess the
effect of DAART on the acquisition of new drug resis-
tance mutations. Finally, ours will be among the few
studies to measure adherence with EAM in both the
DAART and SAT arms [24]. In the DAART arm, EAM
will be done for both observed doses at the OTP and
for self-administered doses taken on nights and
weekends. A study conducted in prisons found that
EAM for doses ‘observed’ by medical staff was lower
than that documented in medication administration
records [36], highlighting the importance of using con-
sistent measurement techniques for self-administered
and “observed” dosing.
An important limitation of our study is the relatively
small sample size, which limits our ability to detect
small, but potentially clinically meaningful, differences
between study conditions. Slow enrollment to our study
was multifactorial. We encountered lower prevalences of
HIV at the OTPs than expected, although pre-study
estimates were based on limited data. Additionally, once
we had screened the population at an OTP, we were
dependent on slot turnover for new candidates. As can
be seen in the Figure, the predominant reason for exclu-
sion was stable ART use with suppressed viral load,
which accounted for 70% of exclusions. This may be a
positive finding that reflects improving access to ART
among HIV-infected drug users during the study period
compared to the late 1990s [37]. One way to address
slow enrollment would have been to include participants
who were taking ART and had suppressed viral loads, as
has been done in other studies [6,23]. However, we
chose not to enroll such participants because we were
concerned that the intervention could have heteroge-
neous effects in individuals who were failing (or not tak-
ing) therapy and those who were doing well with
treatment. Consequently, our study population is
restricted to those participants most in need of interven-
tion - those not taking ART when indicated or experien-
cing virologic failure on ART.
The second most common reason for exclusion was
disengagement from HIV care, absence of active insur-
ance coverage, or failure to obtain ART prescription,
Table 1 Baseline characteristics of HIV-infected participants enrolled in a randomized trial comparing directly adminis-
tered antiretroviral therapy to self administered therapy in opioid treatment programs, Baltimore, Maryland
(Continued)
NRTIs only 1 (1)
Other 7 (7)
Drug classes included in antiretroviral regimen (not mutually exclusive)
NRTI 97 (91)
Ritonavir-boosted PI 85 (79)
PI (not boosted with ritonavir) 4 (4)
NNRTI 21 (20)
Integrase inhibitor 7 (7)
Dosing frequency of prescribed antiretroviral regimen
Once daily 65 (61)
Twice daily 42 (39)
PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor.
aValues are frequency (%) or median (interquartile range).
bCenter for Epidemiologic Studies Depression (CES-D) Scale (7). Higher values indicate more numerous or more severe depressive symptoms (range 0 to 30).
cFrom 106 subjects.
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individuals good candidates for the trial and made
efforts to assist them by scheduling appointments with
HIV providers, providing appointment reminders, and
assisting with paperwork. However, particularly at sites
where on-site HIV care was not available, such efforts
were often unsuccessful. This highlights the importance
of addressing basic access and engagement to care in
trials of medication adherence interventions. In general,
willingness to join the study was not a substantial bar-
rier to recruitment, with only 12 individuals declining to
participate. The majority (9) of these subjects were from
a single site, which was the only site that did not have
on-site HIV or medical care. Anecdotally, individuals at
this site were more apt to cite confidentiality concerns
as barriers to joining than individuals at other sites.
In summary, we recently completed enrollment for a
randomized controlled trial comparing DAART to SAT
among HIV-infected participants attending OTPs.
Important clinical questions remain about whether
DAART is a useful adherence strategy, and if so, in
which populations and under what implementation
models. Our study will contribute to existing data on
this topic and guide future approaches.
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